STUDY OBJECTIVES: To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults. DESIGN: This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment periods. Overnight polysomnography was performed at baseline, Week 8, and Week 28. SETTING:Single-center study conducted from August 2008 to September 2009. PARTICIPANTS: Forty-five subjects with moderate to severe OSA not receiving positive airway pressure (PAP) treatment with body mass index of 30-40 kg/m(2). INTERVENTIONS: Subjects were randomized to receive placebo (n = 23) or phentermine 15 mg plus extended-release topiramate 92 mg (n = 22). Both groups received lifestyle-modification counseling. MEASUREMENTS AND RESULTS: Primary endpoint, change in apnea-hypopnea index (AHI), significantly favored phentermine 15 mg plus extended-release topiramate 92 mg (-31.5 events/h, 95% CI: -40.0, -22.9) over placebo (-16.6 events/h, 95% CI: -25.0, -8.2) at Week 28 (P =0.0084). At Week 28, there was a 10.2% (95% CI: -12.7, -7.6; 10.8 kg, 95% CI: -13.5, -8.0) mean decrease in weight in the phentermine 15 mg plus extended-release topiramate 92 mg group compared with 4.3% (95% CI: -6.6, -2.0; 4.7 kg, 95% CI: -7.2, -2.2) in the placebo group (P = 0.0006) and a positive, significant (P = 0.0003) correlation between percent change in weight and change in AHI. Significant improvements in overnight oxygen saturation and reduction in blood pressure compared with placebo were observed. Phentermine 15 mg plus extended-release topiramate 92 mg was well tolerated with low adverse event rates. CONCLUSIONS:Phentermine 15 mg plus extended-release topiramate 92 mg induced significant weight reductions and concomitant improvements in OSA and related symptoms vs placebo. This suggests weight loss mediated by phentermine 15 mg plus extended-release topiramate 92 mg may be useful in treatment of moderate to severe OSA in obese subjects unable or unwilling to comply with PAP treatment.
RCT Entities:
STUDY OBJECTIVES: To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults. DESIGN: This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment periods. Overnight polysomnography was performed at baseline, Week 8, and Week 28. SETTING: Single-center study conducted from August 2008 to September 2009. PARTICIPANTS: Forty-five subjects with moderate to severe OSA not receiving positive airway pressure (PAP) treatment with body mass index of 30-40 kg/m(2). INTERVENTIONS: Subjects were randomized to receive placebo (n = 23) or phentermine 15 mg plus extended-release topiramate 92 mg (n = 22). Both groups received lifestyle-modification counseling. MEASUREMENTS AND RESULTS: Primary endpoint, change in apnea-hypopnea index (AHI), significantly favored phentermine 15 mg plus extended-release topiramate 92 mg (-31.5 events/h, 95% CI: -40.0, -22.9) over placebo (-16.6 events/h, 95% CI: -25.0, -8.2) at Week 28 (P =0.0084). At Week 28, there was a 10.2% (95% CI: -12.7, -7.6; 10.8 kg, 95% CI: -13.5, -8.0) mean decrease in weight in the phentermine 15 mg plus extended-release topiramate 92 mg group compared with 4.3% (95% CI: -6.6, -2.0; 4.7 kg, 95% CI: -7.2, -2.2) in the placebo group (P = 0.0006) and a positive, significant (P = 0.0003) correlation between percent change in weight and change in AHI. Significant improvements in overnight oxygen saturation and reduction in blood pressure compared with placebo were observed. Phentermine 15 mg plus extended-release topiramate 92 mg was well tolerated with low adverse event rates. CONCLUSIONS:Phentermine 15 mg plus extended-release topiramate 92 mg induced significant weight reductions and concomitant improvements in OSA and related symptoms vs placebo. This suggests weight loss mediated by phentermine 15 mg plus extended-release topiramate 92 mg may be useful in treatment of moderate to severe OSA in obese subjects unable or unwilling to comply with PAP treatment.
Authors: Juan F Masa; Jaime Corral; Ricardo Pereira; Joaquin Duran-Cantolla; Marta Cabello; Luis Hernández-Blasco; Carmen Monasterio; Alberto Alonso; Eusebi Chiner; Jose Zamorano; Felipe Aizpuru; Jose M Montserrat Journal: Am J Respir Crit Care Med Date: 2011-07-07 Impact factor: 21.405
Authors: Ronald R Grunstein; Kaj Stenlöf; Jan A Hedner; Markku Peltonen; Kristjan Karason; Lars Sjöström Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Krista L Haines; Lana G Nelson; Rodrigo Gonzalez; Tracy Torrella; Taylor Martin; Ali Kandil; Robert Dragotti; William M Anderson; Scott F Gallagher; Michel M Murr Journal: Surgery Date: 2006-12-08 Impact factor: 3.982
Authors: Kari Johansson; Erik Hemmingsson; Richard Harlid; Ylva Trolle Lagerros; Fredrik Granath; Stephan Rössner; Martin Neovius Journal: BMJ Date: 2011-06-01
Authors: Ian J Neeland; Bjorn Eliasson; Takatoshi Kasai; Nikolaus Marx; Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Isabella Zwiener; Brian S Wojeck; Henry K Yaggi; Odd Erik Johansen Journal: Diabetes Care Date: 2020-10-01 Impact factor: 19.112